Latest news with #Rituximab
Medscape
29-07-2025
- Health
- Medscape
Rituximab No Better Than Standard Therapy for EGPA Remission
TOPLINE: Rituximab did not show superiority over conventional therapy in inducing remission in patients with eosinophilic granulomatosis with polyangiitis (EGPA). Both treatment groups had similar remission rates at 180 and 360 days, with no significant differences in relapse rates or adverse events. METHODOLOGY: A phase 3, multicenter, randomized, controlled superiority trial was conducted in France to compare rituximab with conventional therapy for EGPA remission induction. A total of 105 adult patients with active EGPA (mean age, 58.4 years; 52.4% women), defined by a Birmingham Vasculitis Activity Score (BVAS, version 3) ≥ 3, were enrolled between December 2016 and October 2019 and randomly assigned to receive either rituximab (n = 52) or conventional therapy on the basis of the five-factor score (n = 53). Patients in the rituximab group received 1 g of rituximab on days 1 and 15, along with glucocorticoids on a tapering schedule; those with a five-factor score ≥ 1 received placebo-cyclophosphamide and placebo-uromitexan. The conventional therapy group received glucocorticoids on a tapering schedule with or without cyclophosphamide on the basis of a five-factor score ≥ 1. The primary endpoint was the proportion of patients who achieved remission, defined as the absence of EGPA disease activity (indicated by a BVAS of 0 at a prednisone dose of ≤ 7.5 mg/d), at 180 days. Secondary endpoints included the duration of remission, glucocorticoid dose, and safety, with follow-up visits scheduled up to 360 days. TAKEAWAY: At 180 days, 63.5% of patients in the rituximab group and 60.4% in the conventional group achieved remission (relative risk, 1.05; P = .75). At 360 days, remission rates were similar between the groups: 59.6% in the rituximab group and 64.2% in the conventional group. The time to remission was a median of 2 weeks in both the groups. Among patients who achieved a BVAS of 0, the mean duration of remission was comparable — 48.5 weeks for rituximab and 49.1 weeks for conventional therapy. No significant differences were observed in relapse rates or serious adverse event rates between the rituximab and conventional therapy groups. Infections and cardiovascular events were the most common serious adverse events. IN PRACTICE: 'On the basis of the results of this trial, the role of rituximab in the therapeutic management of EGPA has been updated,' the authors of the study wrote. 'In most of the study population with nonsevere EGPA, the lack of a clinically meaningful effect of rituximab in addition to the conventional strategy of glucocorticoids alone may appropriately inform clinical decision-making,' they added. SOURCE: The study was led by Benjamin Terrier, MD, PhD, Université Paris Cité in Paris, France. It was published online on July 28, 2025, in Annals of Internal Medicine. LIMITATIONS: The study's design as a superiority trial may not adequately address the equivalence between rituximab and conventional therapy. The limited sample size, due to the rarity of EGPA, affected the precision of subgroup analyses. The focus on remission induction in the vasculitis phase may differ from other studies. DISCLOSURES: The study was funded by research grants from the French Ministry of Health and sponsored by Assistance Publique-Hôpitaux de Paris. Additional disclosures are noted in the original article online. This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.
Medical News Today
16-07-2025
- Health
- Medical News Today
Rituxan for rheumatoid arthritis (RA)
Rituxan (rituximab) is a brand-name intravenous (IV) infusion prescribed for RA. This article covers topics such as side effects, dosage, and how Rituxan works for is a biologic and belongs to a drug class called monoclonal antibodies. The medication is available in several biosimilar on for more information about Rituxan for has boxed warnings. A boxed warning is the most serious warning from the Food and Drug Administration (FDA). For details, see the 'Before receiving Rituxan' section.»Learn more about Rituxan explainedRheumatoid arthritis (RA) is an autoimmune condition that typically affects the RA, your immune system mistakenly attacks healthy tissue in the joints. This can cause symptoms that affect the wrists, hands, knees, ankles, and of RASymptoms of RA may include:joint pain, stiffness, or swellingfatigueskin lumpsWho Rituxan is prescribed forRituxan is prescribed for adults with moderate to severe symptoms of RA. Doctors prescribe Rituxan when tumor necrosis factor (TNF) blocker drugs haven't worked well for managing Rituxan treats RA RA happens when the immune system mistakenly attacks healthy tissue in the works by targeting a protein called CD20, which is found on certain immune cells. This protein is thought to play a role in an overactive immune system. By blocking CD20, Rituxan helps reduce inflammation and ease RA learn more about how Rituxan works, talk with your doctor. How well Rituxan works for RAIn clinical trials, Rituxan was shown to be effective in treating learn more about how the drug performed in clinical trials, refer to Rituxan's prescribing information. You can also talk with your doctor or visit the drug manufacturer's Rituxan for RABelow is information about the dosage of Rituxan for RA in adults. Your doctor will determine the dosage that's suitable for your treating RA, the usual dosage of Rituxan is two doses of 1,000 milligrams (mg) given 2 weeks apart. This is considered one treatment course. You'll typically receive one treatment course of Rituxan every 16 to 24 is prescribed along with methotrexate (Otrexup, Rasuvo, and others) for RA. Your doctor will explain the methotrexate dosage that's right for In addition to treating RA, Rituxan has other uses. Keep in mind that the drug's dosage may differ when treating other conditions. To learn more, talk with your to receive RituxanYour doctor or another healthcare professional will give Rituxan as an IV infusion. An IV infusion is an injection into a vein that's given over a period of time. Rituxan infusions are typically given over several often Rituxan is givenFor RA, you'll receive two infusions of Rituxan 2 weeks apart. This counts as one round of on your treatment plan, you'll receive another round of treatment every 16 to 24 weeks.»Learn more about the dosing protocols for Rituxan. Rituxan side effects The use of Rituxan for RA may cause side effects that are mild or serious. Rituxan is also approved to treat several other conditions. It's important to note that side effects from Rituxan may differ depending on the condition it's used to lists below include some of the main side effects that have been reported with Rituxan. For information about other potential side effects of the drug, talk with your doctor or pharmacist. You can also refer to Rituxan's prescribing After the Food and Drug Administration (FDA) approves a drug, it tracks and reviews side effects of the medication. Sharing your experience helps make medications safer for everyone by giving doctors and researchers more information about how the drug works in real life. If you develop a side effect while receiving Rituxan and want to tell the FDA about it, visit MedWatch or call 800-FDA-1088.»Get more information about Riutxan's side side effects of RituxanThese are some mild side effects that may occur with Rituxan for RA:mild infection, such as urinary tract infection (UTI)fever or chillsindigestionitchingjoint painrunny noseThese side effects of Rituxan may be temporary, lasting a few days to weeks. But if they last longer than this, bother you, or become severe, it's important to talk with your doctor or side effects of RituxanBelow are serious side effects that can occur with Rituxan:serious infection, such as shinglesheart problems, such as ventricular fibrillation (a type of irregular heart rhythm)infusion-related reactions*severe reactions affecting the mucous membranes or skin*hepatitis B reactivation*progressive multifocal leukoencephalopathy (PML)*Call your doctor right away if you develop serious side effects while using Rituxan. If the side effects seem life threatening or you think you're having a medical emergency, call 911 or your local emergency number immediately.* Rituxan has a boxed warning for this side effect. A boxed warning is the most serious warning from the FDA. To learn more, see the 'Before receiving Rituxan' section. ALLERGIC REACTIONFor some people, Rituxan can cause an allergic reaction. In general, symptoms of allergic reaction can be mild or to manageFor mild allergic reaction symptoms, such as a mild rash, call your doctor right away. They may recommend treatments to help manage your symptoms. They'll also let you know whether you should continue treatment with severe allergic reaction symptoms, such as swelling or trouble breathing, call 911 or your local emergency number right away. These symptoms require immediate medical care as they can become life threatening. If you've had a serious allergic reaction to Rituxan, your doctor may recommend a different medication receiving RituxanBefore you receive Rituxan, there's some important information to keep in mind. The drug may not be a safe option if you have certain medical conditions or other factors that affect your health. Some of these are mentioned warningsThis drug has several boxed warnings. These are the most serious warnings from the Food and Drug Administration (FDA).Infusion-related reactionsRituxan treatment may cause infusion-related reactions during or after your dose. In rare cases, infusion reactions may be of infusion reactions may include:swelling of your face and lipslow blood pressuredifficulty breathingYour doctor may give you medications to help reduce the risk of infusion reactions. These may include acetaminophen (Tylenol) and an antihistamine, such as diphenhydramine (Benadryl).If you have symptoms of an infusion reaction while receiving Rituxan or after, tell your doctor right away. They'll likely pause or stop your Rituxan treatment. Severe reactions affecting the mucous membranes or skinTreatment with Rituxan may cause severe reactions that affect your skin or mucous membranes (lining inside your mouth). These may include life threatening reactions such as Stevens-Johnson syndrome and toxic epidermal of these reactions may include:skin sores or blisterspeelingpain around the affected areaTell your doctor right away if you have symptoms of a mucous membrane or skin reaction. They'll likely stop your Rituxan treatment and manage your symptoms. Hepatitis B reactivation Rituxan may reactivate symptoms of hepatitis B in people who've ever had the hepatitis B virus (HBV). Reactivation of hepatitis B can lead to liver failure or be life of hepatitis B may include:jaundiceabdominal paindark urineDoctors typically test for HBV before and during Rituxan treatment. If the test shows HBV, they may treat it before prescribing Rituxan. Doctors may watch for hepatitis B reactivation for up to 2 years after the final dose of you have symptoms of hepatitis B, contact your doctor right away. They may temporarily stop Rituxan treatment until the infection is Rituxan may increase the risk of PML. This is a rare but serious brain infection that may be fatal in extreme of PML may include:weakness on one side of the bodychanges in memory, personality, or visionconfusiondifficulty speakingIf you have symptoms of PML after receiving Rituxan, tell your doctor right away. They'll likely stop your Rituxan treatment and manage your symptoms. Other warningsIn addition to boxed warnings, Rituxan has other warnings. If any of the following medical conditions or other health factors are relevant to you, talk with your doctor before receiving Rituxan:if you have an infectionif you have a heart problemif you have a lung problemif you have a kidney problemif you're pregnant or breastfeedingif you've had an allergic reaction to Rituxan or any of its ingredientsFrequently asked questionsKeep reading for answers to some frequently asked questions about Rituxan for I receive Rituxan for RA without methotrexate?Not usually, unless your doctor recommends it. Rituxan is typically prescribed together with methotrexate (Otrexup, Rasuvo, others) for RA. If you're unable to take methotrexate for any reason, such as side effects or other health conditions, talk with your doctor. They can recommend whether Rituxan or another treatment option may be better for you. Is there anything I should avoid after a Rituxan infusion for RA?Your doctor can recommend whether to avoid anything specific after a Rituxan people feel tired or have mild body aches within a few hours of the infusion. It may be helpful to plan for rest after your appointment, especially after your first you have other questions about what to expect with Rituxan infusions, talk with your Rituxan chemotherapy or immunotherapy for RA?Rituxan is a type of immunotherapy for RA, but it isn't a works by helping to ease an overactive immune system. Rituxan does this by specifically targeting a protein called CD20 on certain immune can be used with chemotherapy to treat certain cancers. Chemotherapy works by killing all rapidly dividing cells. This includes some healthy cells along with cancer cells, which is why chemotherapy often causes widespread side you have other questions about how Rituxan works, talk with your cost and savingsThe cost of Rituxan is based on several factors. These include your prescribed treatment regimen, your insurance plan, and your location. The price also depends on the cost of the appointment to receive doses of Rituxan from a healthcare is a brand-name drug that's available in the following biosimilar versions: Riabni (rituximab-arrx)Ruxience (rituximab-pvvr)Truxima (rituximab-abbs)Brand-name drugs usually cost more than biosimilars. To learn about this drug's bioimilar versions, talk with your doctor or pharmacist.»Learn more about Rituxan and cost and Medical News Today has made every effort to make certain that all information is factually correct, comprehensive, and up to date. However, this article should not be used as a substitute for the knowledge and expertise of a licensed healthcare professional. You should always consult your doctor or another healthcare professional before taking any medication. The drug information contained herein is subject to change and is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. The absence of warnings or other information for a given drug does not indicate that the drug or drug combination is safe, effective, or appropriate for all patients or all specific uses.
Time of India
06-07-2025
- Health
- Time of India
Costly Drug Now Free For Needy Patients With Rare Skin Disease: Doctors & NGO
Nagpur: Needy patients suffering from a rare and painful skin disorder, Autoimmune Blistering Disease, can now receive the costly drug, Rituximab, free of charge, thanks to the initiative by the Pune-based foundation, AIBDF. The announcement came during a doctors' and public awareness programme organised by the Vidarbha Dermatology Society (VDS) attended by over 200 dermatologists from across Vidarbha. "This disease is rare but deadly, and incredibly painful. Our foundation provides Rituximab injection free of cost to needy patients so they can access the best treatment," said Dr Vikrant Saoji, a senior dermatologist. Suratwala explains that he started AIBDF in memory of his late wife, Jayshree Suratwala, who tragically lost her life to this disease during the pandemic. "I wanted to ensure that no one else suffers the way she did," he said. Senior dermatologist Dr Vinit Dubey from Chandrapur sent the very first patient to AIBDF in 2023. "The patient came from a very poor family," he said, adding, "Thanks to AIBDF, my patient received the expensive medicine for free and is now doing well." Dr Asra Khumushi, president of VDS, says the initiative is a game-changer for many underprivileged patients. "I have several patients with autoimmune blistering diseases, and many come from low-income backgrounds. Steroids are often prescribed but have severe side effects. Rituximab is the most proven and effective drug. Thanks to this NGO, it's possible now for many poor patients to get this treatment," Dr Khumushi explains. Dr Nitin Barde, another dermatologist, highlighted the financial relief for patients. "The entire treatment still adds up to around Rs one lakh. The foreign version costs over Rs three lakh per dose. So, getting this drug free of cost is a huge relief for patients," he says. Jayant Hemade, co-founder of AIBDF, and a family friend of Suratwala, said the NGO has far helped 25 patients. "Until now, the foundation was entirely funded by Suratwala. But we've recently secured CSR certification and will start accepting corporate support," Hemade said. He urged both patients and dermatologists to spread the good word. VDS secretary Dr Priyanka Magia discussed the importance of early diagnosis. "Hundreds of dermatologists across Vidarbha are now aware of this service. I urge anyone experiencing symptoms of this disease to consult a dermatologist as soon as possible, because patients must go through specialists to avail this benefit," Dr Magia advises. According to doctors, AIIMS Nagpur treated 70 patients with autoimmune blistering diseases in the past three years, highlighting the growing need for accessible treatment in the region. Autoimmune Blistering Diseases (AIBDs) * Rare but potentially life-threatening skin disorders * Immune system mistakenly attacks skin and mucous membranes * Causes painful blisters, sores, infections * AIIMS Nagpur treated 70 patients in just 3 years — significant for such a rare illness * Often treated with steroids, but these have serious side effects * Rituximab is the most proven and effective drug * AIBDF now provides Rituximab free of cost to needy patients * 25 patients helped so far by the foundation
Time of India
17-06-2025
- Health
- Time of India
Transplant triumph: How science and a grandfather's gift helped save 5-year-old
Dr Chattopadhyay with his young patient and her family Dr Somnath Chattopadhyay When little Kavya came to us, she was just five years old but already carrying the heavy burden of a rare liver disease called Biliary Atresia. It's a condition in which the bile ducts inside the liver are either blocked or missing, so bile cannot drain properly. This causes the liver to get damaged and scarred over time. Sadly, without a transplant, the damage is often fatal. Kavya's story was especially close to my heart because her elder sister, Dhruvi, had battled a similar illness a decade ago. Dhruvi was four when we placed a part of her mother's liver in her tiny abdomen. She recovered successfully and was now a sprightly teen. Seeing that family's journey — the hope, struggles, the triumphs — was deeply moving. So, when Kavya needed a transplant, we knew we were fighting not just for her life but carrying forward a shared hope. Usually, when a child needs a liver transplant, one of the parents donates a part of their liver. It's a complex but common practice because blood group compatibility is simpler, and the parents are naturally the first choice. But in Kavya's case, it wasn't that simple. Her mother had already donated for Dhruvi, and her father wasn't eligible because he had fatty liver disease. by Taboola by Taboola Sponsored Links Sponsored Links Promoted Links Promoted Links You May Like Free P2,000 GCash eGift UnionBank Credit Card Apply Now Undo It was then that her 70-year-old grandfather stepped in without hesitation. Now, here's where the challenge really began. Kavya's blood group was A positive, while her grandfather's was B positive — a mismatch that would typically make transplantation nearly impossible. To complicate matters further, Kavya's immune system had already developed antibodies against her grandfather's blood type. These antibodies are like tiny soldiers that recognise and attack anything foreign, including the donated liver. This mismatch and the existing antibodies could have led to immediate rejection of the transplant, risking Kavya's life. But we found a crucial piece of hope. When we measured the levels of these antibodies in Kavya's blood, they weren't as high as we had feared. This meant there was a real chance to control her immune system enough to accept the new liver. Our plan was twofold. First, we gave Kavya a medicine called Rituximab. It sounds complicated, but Rituximab works by calming down the immune cells that make those harmful antibodies. Think of it as turning down the volume on the part of the immune system that would otherwise attack the transplant. Second, we performed plasma exchange therapy. Imagine your blood as a river, with plasma as the liquid part that carries antibodies. Through plasma exchange, we 'washed out' the harmful antibodies by removing some of her plasma and replacing it with clean plasma. This process helps to clear away the soldiers ready to attack the new liver. It was a delicate dance, and every step had to be perfectly timed and executed. We knew that if even a small number of these antibodies remained, Kavya's body could reject the new liver immediately, which is often fatal. Adding to the challenge, Kavya had undergone major surgery as an infant. This had left scar tissue inside her abdomen, making the transplant surgery more complicated and riskier. Our team used advanced imaging to carefully plan how the grandfather's liver segment would fit inside Kavya's small abdomen, ensuring it wouldn't cause harm or pressure. The family's courage was remarkable throughout. Having already walked this path with their elder daughter, they understood what lay ahead. Yet, the financial strain was very real. The Jains are a modest family. Kavya's mother reached out to NGOs for support. Our hospital's trust also stepped in to help ease the burden somewhat. In Kavya's case, the parents couldn't donate. Her mom had already donated for Dhruvi, and her father had fatty liver disease. It was then that her 70-year-old grandfather stepped up Dr Chattopadhyay As for her grandfather, he underwent a series of tests — blood work, scans, heart checks — to ensure he was healthy enough to donate part of his liver. Donating a piece of your liver is a major decision. It involves surgery, pain, recovery, and risk. We make sure donors understand everything clearly and often connect them with people who have donated before. But in the Jains' case, their previous experience had prepared them emotionally and mentally. On Feb 22, Kavya was admitted. Two weeks later, the big day arrived. For ten intense hours, two surgical teams worked, connecting the liver to her blood vessels and bile ducts with utmost precision. Watching Kavya recover after surgery was incredibly rewarding. She was discharged in three weeks. Her grandfather, too, recovered well and was back to work in just seven days. Just a few decades ago, a transplant like this would have been unthinkable. Transplants across blood group barriers almost always ended in rejection. But advances in medicines like Rituximab and improved plasma exchange techniques have revolutionised what's possible. India has become a leader in living donor liver transplantation. This progress came from necessity — due to fewer deceased donors — but also from innovation, skill, and determination. Today, we perform more living donor liver transplants than any other country, often at a fraction of the cost seen in Western nations. To families facing the frightening prospect of paediatric liver disease and transplantation, my message is simple: don't lose hope. While it may feel overwhelming, these transplants have excellent success rates. Children go on to live full, vibrant lives — going to school, pursuing careers, building families. And while the idea of transplantation can be scary, it's safer today than ever before. Donors' livers regenerate, making living donation a powerful and safe gift. Dr Chattopadhyay is consultant and head of Hepato-Pancreato-Biliary Surgery and Liver Transplant at Kokilaben Dhirubhai Ambani Hospital, Mumbai. He spoke to Sharmila Ganesan Ram One step to a healthier you—join Times Health+ Yoga and feel the change
Globe and Mail
12-06-2025
- Business
- Globe and Mail
Diffuse Large B-Cell Clinical Trial Analysis: Key Insights into Rich Pipeline Featuring 70+ Companies and 75+ Therapies
DelveInsight's, ' Diffuse Large B-Cell Lymphoma Pipeline Insight 2025 ' report provides comprehensive insights about 70+ companies and 75+ pipeline drugs in Diffuse Large B-Cell Lymphoma pipeline landscape. It covers the Diffuse Large B-Cell Lymphoma pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Diffuse Large B-Cell Lymphoma therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive Diffuse Large B-Cell Lymphoma pipeline products in this space. Stay ahead with the latest insights! Download DelveInsight's comprehensive Diffuse Large B-Cell Lymphoma Pipeline Report to explore emerging therapies, key Diffuse Large B-Cell Lymphoma Companies, and future Diffuse Large B-Cell Lymphoma treatment landscapes @ Diffuse Large B-Cell Lymphoma Pipeline Outlook Report Key Takeaways from the Diffuse Large B-Cell Lymphoma Pipeline Report In June 2025, Genmab announced a study will assess how safe and effective epcoritamab plus lenalidomide (E-Len) is compared to rituximab plus gemcitabine and oxaliplatin (R-GemOx) )in treating adult participants with relapsed or refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL). Adverse events and change in disease condition will be assessed. In June 2025, Mitsubishi Tanabe Pharma Corporation conducted a phase I/II Open-Label Study of MT-2111 in Patients With Relapsed/Refractory DLBCL. DelveInsight's Diffuse Large B-Cell Lymphoma pipeline report depicts a robust space with 70+ active players working to develop 75+ pipeline therapies for Diffuse Large B-Cell Lymphoma treatment. The leading Diffuse Large B-Cell Lymphoma Companies such as Miltenyi Biomedicine, Adicet Bio, VelosBio, Novartis Pharmaceuticals, Sanofi, Eisai Co, Schrodinger, Sana Biotechnology, Ranok Therapeutics, Monte Rosa Therapeutic, Otsuka Pharmaceutical, OncoNano Medicine, Regeneron Pharmaceuticals, Hoffmann-La Roche, Celgene, Nurix Therapeutics, NovalGen, Nektar Therapeutics, Genentech, CSPC ZhongQi Pharmaceutical Technology and others. Promising Diffuse Large B-Cell Lymphoma Therapies such as Ibrutinib, Bendamustine, Rituximab, R-miniCHOP, Selinexor, Tafasitamab, Lenalidomide, and others. Discover how the Diffuse Large B-Cell Lymphoma treatment paradigm is evolving. Access DelveInsight's in-depth Diffuse Large B-Cell Lymphoma Pipeline Analysis for a closer look at promising breakthroughs @ Diffuse Large B-Cell Lymphoma Clinical Trials and Studies Diffuse Large B-Cell Lymphoma Emerging Drugs Profile Brentuximab vedotin: Pfizer Brentuximab vedotin (Adcetris) is an anti-neoplastic agent. It is indicated for the treatment of patients with Classical Hodgkin lymphoma (HL) after failure of autologous hematopoietic stem cell transplantation (auto-HSCT) or after failure of at least two prior multi-agent chemotherapy regimens in patients who are not auto-HSCT candidates. Adcetris is also indicated for the treatment of adult patients with CD30+ Hodgkin lymphoma at increased risk of relapse or progression following autologous stem cell transplant (ASCT), also indicated for the treatment of adult patients with relapsed or refractory systemic anaplastic large cell lymphoma, for the treatment of adult patients with primary cutaneous anaplastic large cell lymphoma (pcALCL) and CD30-expressing mycosis fungoides (MF) who have received prior systemic therapy, for the treatment of adult patients with relapsed or refractory CD30+ cutaneous T- cell lymphoma (CTCL) after at least 1 prior systemic therapy. Adcetris is indicated for the first-line pediatric treatment for CD30-positive Hodgkin lymphoma. Currently, the drug is in Phase III stage of its clinical trial for the treatment of Diffuse Large B Cell Lymphoma. THOR-707: Sanofi THOR-707 is a precisely PEGylated version of IL-2, where the PEG chain is attached to a novel amino acid inserted at a location on IL-2 that prevents it from engaging the alpha-receptor and binding to immune receptors that cause drug toxicities (IL-2R-alpha, CD25). The engineered IL-2 retains near-native binding to the beta-gamma receptors that selectively expand tumor-killing T effector cells and Natural Killer (NK) cells without the alpha-mediated immunosuppressive effects of regulatory T cells or eosinophil-mediated vascular leak syndrome. Currently, the drug is in Phase II stage of its clinical trial for the treatment of Diffuse Large B Cell Lymphoma. Abexinostat: Xynomic Pharmaceuticals Abexinostat (Xynomic Pharmaceuticals) is a broad histone deacetylase (HDAC) inhibitor. HDAC enzymes (also known as lysine deacetylase) cleave acetyl groups from N-acetyl lysine amino acids on a histone. HDAC inhibition leads to highly acetylated histones and chromatin reshaping. In addition to altering histone acetylation, HDAC inhibitors can also influence the degree of acetylation on non-histone proteins, increasing or repressing their activity. Currently, the drug is in Phase II stage of its clinical trial for the treatment of Diffuse Large B-cell lymphoma. RNK05047: Ranok Therapeutics RNK05047 is a first-in-class, small-molecule, tumor- and BRD4-selective protein degrader that was discovered and developed using Ranok's proprietary approach to targeted protein degradation, CHAMPTM. The bromodomain transcription factor BRD4 is a key regulator of oncogenes such as MYC and BCL2 and is involved in diverse cancer types. CHAMP-1 is a Phase I/II trial of RNK05047 currently underway in the US that will assess its safety, tolerability, and pharmacokinetics, and also includes measures of anti-tumor activity and pharmacodynamics readouts as secondary endpoints. BMF-219: Biomea Fusion BMF-219 is an oral investigational covalent menin inhibitor. Data suggests that optimized covalent inhibitors can provide deeper inhibition while being better tolerated than some conventional reversible inhibitors. BMF-219 is being developed for genetically defined AML, ALL, DLBCL, MM and CLL patients. BMF-219 blocks the interaction of menin and MLL (AML, ALL), and limits the activity and/or expression of NPM1, MYC, HOX, and MEIS1, all known drivers of oncogenic proliferation and survival. Currently, the drug is in Phase I stage of its clinical trial for the treatment of Diffuse Large B Cell Lymphoma. ADI-001: Adicet Bio ADI-001 is an investigational allogeneic gamma delta CAR T cell therapy being developed as a potential treatment for relapsed or refractory B-cell NHL. ADI-001 targets malignant B-cells via an anti-CD20 CAR and via the gamma delta innate and T cell endogenous cytotoxicity receptors. Gamma delta T cells engineered with an anti-CD20 CAR have demonstrated potent anti-tumor activity in preclinical models, leading to long-term control of tumor growth. In April 2022, ADI-001 was granted Fast Track Designation by the FDA for the potential treatment of relapsed or refractory B-cell NHL. Currently, the drug is in Phase I stage of its clinical trial for the treatment of Diffuse Large B Cell Lymphoma. The Diffuse Large B-Cell Lymphoma pipeline report provides insights into The report provides detailed insights about companies that are developing therapies for the treatment of Diffuse Large B-Cell Lymphoma with aggregate therapies developed by each company for the same. It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Diffuse Large B-Cell Lymphoma Treatment. Diffuse Large B-Cell Lymphoma Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects. Diffuse Large B-Cell Lymphoma Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Diffuse Large B-Cell Lymphoma market. Get a detailed analysis of the latest innovations in the Diffuse Large B-Cell Lymphoma pipeline. Explore DelveInsight's expert-driven report today! @ Diffuse Large B-Cell Lymphoma Unmet Needs Diffuse Large B-Cell Lymphoma Companies Miltenyi Biomedicine, Adicet Bio, VelosBio, Novartis Pharmaceuticals, Sanofi, Eisai Co, Schrodinger, Sana Biotechnology, Ranok Therapeutics, Monte Rosa Therapeutic, Otsuka Pharmaceutical, OncoNano Medicine, Regeneron Pharmaceuticals, Hoffmann-La Roche, Celgene, Nurix Therapeutics, NovalGen, Nektar Therapeutics, Genentech, CSPC ZhongQi Pharmaceutical Technology and others. Diffuse Large B-Cell Lymphoma pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as Oral Intravenous Subcutaneous Parenteral Topical Diffuse Large B-Cell Lymphoma Products have been categorized under various Molecule types such as Recombinant fusion proteins Small molecule Monoclonal antibody Peptide Polymer Gene therapy Download DelveInsight's latest report to gain strategic insights into upcoming Diffuse Large B-Cell Lymphoma Therapies and key Diffuse Large B-Cell Lymphoma Developments @ Diffuse Large B-Cell Lymphoma Market Drivers and Barriers, and Future Perspectives Scope of the Diffuse Large B-Cell Lymphoma Pipeline Report Coverage- Global Diffuse Large B-Cell Lymphoma Companies- Miltenyi Biomedicine, Adicet Bio, VelosBio, Novartis Pharmaceuticals, Sanofi, Eisai Co, Schrodinger, Sana Biotechnology, Ranok Therapeutics, Monte Rosa Therapeutic, Otsuka Pharmaceutical, OncoNano Medicine, Regeneron Pharmaceuticals, Hoffmann-La Roche, Celgene, Nurix Therapeutics, NovalGen, Nektar Therapeutics, Genentech, CSPC ZhongQi Pharmaceutical Technology and others. Diffuse Large B-Cell Lymphoma Therapies - Ibrutinib, Bendamustine, Rituximab, R-miniCHOP, Selinexor, Tafasitamab, Lenalidomide, and others. Diffuse Large B-Cell Lymphoma Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination Diffuse Large B-Cell Lymphoma Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III Which companies are leading the race in Diffuse Large B-Cell Lymphoma drug development? Find out in DelveInsight's exclusive Diffuse Large B-Cell Lymphoma Pipeline Report—access it now! @ Diffuse Large B-Cell Lymphoma Emerging Drugs and Major Companies Table of Content Introduction Executive Summary Diffuse Large B-Cell Lymphoma: Overview Pipeline Therapeutics Therapeutic Assessment Diffuse Large B-Cell Lymphoma– DelveInsight's Analytical Perspective Late Stage Products (Phase III) Brentuximab vedotin: Pfizer Drug profiles in the detailed report….. Mid Stage Products (Phase II) THOR-707: Sanofi Drug profiles in the detailed report….. Early Stage Products (Phase I) ADI-001: Adicet Bio Drug profiles in the detailed report….. Preclinical and Discovery Stage Products Drug name: Company name Drug profiles in the detailed report….. Inactive Products Diffuse Large B-Cell Lymphoma Key Companies Diffuse Large B-Cell Lymphoma Key Products Diffuse Large B-Cell Lymphoma- Unmet Needs Diffuse Large B-Cell Lymphoma- Market Drivers and Barriers Diffuse Large B-Cell Lymphoma- Future Perspectives and Conclusion Diffuse Large B-Cell Lymphoma Analyst Views Diffuse Large B-Cell Lymphoma Key Companies Appendix About Us DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve. Media Contact Company Name: DelveInsight Business Research LLP Contact Person: Yash Bhardwaj Email: Send Email Phone: 09650213330 Address: 304 S. Jones Blvd #2432 City: Las Vegas State: NV Country: United States Website:
